keyword
MENU ▼
Read by QxMD icon Read
search

Hairy cell leukaemia

keyword
https://www.readbyqxmd.com/read/28611188/new-quantitative-features-for-the-morphological-differentiation-of-abnormal-lymphoid-cell-images-from-peripheral-blood
#1
Laura Puigví, Anna Merino, Santiago Alférez, Andrea Acevedo, José Rodellar
AIMS: This work aims to propose a set of quantitative features through digital image analysis for significant morphological qualitative features of different cells for an objective discrimination among reactive, abnormal and blast lymphoid cells. METHODS: Abnormal lymphoid cells circulating in peripheral blood in chronic lymphocytic leukaemia, B-prolymphocytic leukaemia, hairy cell leukaemia, splenic marginal zone lymphoma, mantle cell lymphoma, follicular lymphoma, T-prolymphocytic leukaemia, T large granular lymphocytic leukaemia and Sézary syndrome, normal, reactive and blast lymphoid cells were included...
June 13, 2017: Journal of Clinical Pathology
https://www.readbyqxmd.com/read/28480198/hairy-cell-leukaemia-variant-with-periarticular-joint-infiltration-and-excellent-radiotherapy-response
#2
Michael J McKay, Kirsty L Rady, Thomas A McKay
Hairy cell leukaemia (HCL) is rare, accounting for only 2% of leukaemias. An even more infrequent variant has been described, HCL-V. The clinicopathologic features of these two entities overlap significantly, although they differ in a number of aspects, including demographics and immunophenotype. In this report, we present the case of a man with HCL-V diagnosed 12 years previously, who is currently haematologically stable with an unusual complication of joint pain due to extensive bony expansion secondary to leukaemic infiltration, and atypical skeletal imaging...
April 2017: Annals of Translational Medicine
https://www.readbyqxmd.com/read/28385698/oral-hairy-leukoplakia-arising-in-a-patient-with-hairy-cell-leukaemia-the-first-reported-case
#3
Gemma Davis, Alexandra Perks, Pemith Liyanage, Konrad Staines
Oral hairy leukoplakia (OHL) is an oral mucosal lesion that is associated with Epstein-Barr virus infection. It commonly presents as an asymptomatic, non-removable white patch on the lateral borders of the tongue in individuals who are immunocompromised. Historically, OHL was thought to be pathognomonic of HIV infection; however, it is now an established phenomenon in a range of conditions affecting immune competence. Hairy cell leukaemia (HCL) is a rare chronic B cell lymphoproliferative disease named after the distinctive cytology of the atypical cells...
April 6, 2017: BMJ Case Reports
https://www.readbyqxmd.com/read/28146266/how-i-manage-patients-with-hairy-cell-leukaemia
#4
REVIEW
Philip A Thompson, Farhad Ravandi
Patients with hairy cell leukaemia (HCL) have highly favourable outcomes after purine analogue therapy. However, most patients subsequently relapse and require re-treatment. A minority of patients develop purine analogue-refractory disease. Targeted therapies have improved outcomes for such patients. Recently, the BRAF V600E mutation was identified in most patients with classical HCL, resulting in constitutive mitogen-activated protein kinase pathway activation; impressive responses are achieved in heavily pre-treated patients with BRAF inhibition...
February 1, 2017: British Journal of Haematology
https://www.readbyqxmd.com/read/27927706/cerebral-tuberculomas-in-a-patient-with-hairy-cell-leukaemia-treated-with-cladribine
#5
Samuel Barbosa Fonseca, Júlio Rodrigues de Oliveira, Cristina Gonçalves, Virgínia Lopes
A 67-year-old man was treated with cladribine for hairy cell leukaemia. A few weeks later, he presented with persistent headaches, intermittent hypoesthesia of the right upper limb and language impairment. Brain CT scan showed 3 contrast-enhancing lesions. MRI revealed infracentimetric nodular lesions with restricted diffusion. One of the lesions was surgically removed and tested positive for acid-fast bacilli. Moreover, Mycobacterium tuberculosis was confirmed by PCR. Antituberculous drugs were prescribed for 12 months, with complete resolution of neurological deficits...
December 7, 2016: BMJ Case Reports
https://www.readbyqxmd.com/read/27808110/structural-characterisation-of-high-affinity-siglec-2-cd22-ligands-in-complex-with-whole-burkitt-s-lymphoma-bl-daudi-cells-by-nmr-spectroscopy
#6
Paul D Madge, Andrea Maggioni, Mauro Pascolutti, Moein Amin, Mario Waespy, Bernadette Bellette, Robin J Thomson, Sørge Kelm, Mark von Itzstein, Thomas Haselhorst
Siglec-2 undergoes constitutive endocytosis and is a drug target for autoimmune diseases and B cell-derived malignancies, including hairy cell leukaemia, marginal zone lymphoma, chronic lymphocytic leukaemia and non-Hodgkin's lymphoma (NHL). An alternative to current antibody-based therapies is the use of liposomal nanoparticles loaded with cytotoxic drugs and decorated with Siglec-2 ligands. We have recently designed the first Siglec-2 ligands (9-biphenylcarboxamido-4-meta-nitrophenyl-carboxamido-Neu5Acα2Me, 9-BPC-4-mNPC-Neu5Acα2Me) with simultaneous modifications at C-4 and C-9 position...
November 3, 2016: Scientific Reports
https://www.readbyqxmd.com/read/27391097/excellent-outcome-of-hairy-cell-leukaemia-with-extensive-mesenteric-infiltration-following-cladribine-therapy
#7
Luis Miguel Juárez Salcedo, Jose Sandoval-Sus, Ling Zhang, Donald Klippenstein, Julio C Chavez
No abstract text is available yet for this article.
September 2016: British Journal of Haematology
https://www.readbyqxmd.com/read/27351754/treatment-outcomes-and-secondary-cancer-incidence-in-young-patients-with-hairy-cell-leukaemia
#8
Bartlomiej M Getta, Kaitlin M Woo, Sean Devlin, Jae H Park, Omar Abdel-Wahab, Alan Saven, Kanti Rai, Martin S Tallman
Repeated therapy of hairy cell leukaemia (HCL) with treatments that have potential long-term toxicities has raised concerns regarding increased risk for younger patients. We compared clinical outcomes and disease complications in 63 patients with HCL aged ≤40 years at diagnosis with 268 patients >40 years treated at Memorial Sloan Kettering Cancer Center. The rate of complete remission following initial therapy was 87% and 83% (P = 0·71) and estimated 10-year overall survival was 100% and 82% (P = 0·25) in younger and older patients, respectively...
November 2016: British Journal of Haematology
https://www.readbyqxmd.com/read/27301277/long-term-durable-remission-by-cladribine-followed-by-rituximab-in-patients-with-hairy-cell-leukaemia-update-of-a-phase-ii-trial
#9
Dai Chihara, Hagop Kantarjian, Susan O'Brien, Jeffrey Jorgensen, Sherry Pierce, Stefan Faderl, Alessandra Ferrajoli, Rebecca Poku, Preetesh Jain, Phillip Thompson, Mark Brandt, Rajyalakshmi Luthra, Jan Burger, Michael Keating, Farhad Ravandi
Nucleoside analogues are highly active in patients with hairy cell leukaemia (HCL); however, patients continue to relapse. This phase II study evaluated the efficacy and safety of cladribine followed by rituximab in patients with untreated HCL (N = 59), relapsed HCL (N = 14) and HCL variant (HCLv, N = 7). Cladribine 5·6 mg/m(2) was given intravenously (IV) daily for 5 d and was followed approximately 1 month later with rituximab 375 mg/m(2) IV weekly for 8 weeks. Complete response rate in patients with untreated HCL, relapsed HCL and HCLv was 100%, 100% and 86%, respectively...
September 2016: British Journal of Haematology
https://www.readbyqxmd.com/read/27066918/hes1-in-immunity-and-cancer
#10
Aradhana Rani, Roseanna Greenlaw, Richard A Smith, Christine Galustian
Hairy and enhancer of split homolog-1 (HES1) is a part of an extensive family of basic helix-loop-helix (bHLH) proteins and plays a crucial role in the control and regulation of cell cycle, proliferation, cell differentiation, survival and apoptosis in neuronal, endocrine, T-lymphocyte progenitors as well as various cancers. HES1 is a transcription factor which is regulated by the NOTCH, Hedgehog and Wnt signalling pathways. Aberrant expression of these pathways is a common feature of cancerous cells. There appears to be a fine and complicated crosstalk at the molecular level between the various signalling pathways and HES1, which contributes to its effects on the immune response and cancers such as leukaemia...
August 2016: Cytokine & Growth Factor Reviews
https://www.readbyqxmd.com/read/26893254/potential-role-of-akt-mtor-signalling-proteins-in-hairy-cell-leukaemia-association-with-braf-erk-activation-and-clinical-outcome
#11
Eleftheria Lakiotaki, Georgia Levidou, Maria K Angelopoulou, Christos Adamopoulos, Gerassimos Pangalis, George Rassidakis, Theodoros Vassilakopoulos, Gabriella Gainaru, Pagona Flevari, Sotirios Sachanas, Angelica A Saetta, Athanasia Sepsa, Maria Moschogiannis, Christina Kalpadakis, Nikolaos Tsesmetzis, Vassilios Milionis, Ilenia Chatziandreou, Irene Thymara, Panayiotis Panayiotidis, Maria Dimopoulou, Eleni Plata, Konstantinos Konstantopoulos, Efstratios Patsouris, Christina Piperi, Penelope Korkolopoulou
The potential role of AKT/mTOR signalling proteins and its association with the Raf-MEK-ERK pathway was investigated in hairy cell leukaemia (HCL). BRAFV600E expression and activated forms of AKT, mTOR, ERK1/2, p70S6k and 4E-BP1 were immunohistochemically assessed in 77 BM biopsies of HCL patients and correlated with clinicopathological and BM microvascular characteristics, as well as with c-Caspase-3 levels in hairy cells. Additionally, we tested rapamycin treatment response of BONNA-12 wild-type cells or transfected with BRAFV600E...
February 19, 2016: Scientific Reports
https://www.readbyqxmd.com/read/26871591/exome-sequencing-in-classic-hairy-cell-leukaemia-reveals-widespread-variation-in-acquired-somatic-mutations-between-individual-tumours-apart-from-the-signature-braf-v-600-e-lesion
#12
Nicola J Weston-Bell, Will Tapper, Jane Gibson, Dean Bryant, Yurany Moreno, Melford John, Sarah Ennis, Hanneke C Kluin-Nelemans, Andrew R Collins, Surinder S Sahota
In classic Hairy cell leukaemia (HCLc), a single case has thus far been interrogated by whole exome sequencing (WES) in a treatment naive patient, in which BRAF V(600)E was identified as an acquired somatic mutation and confirmed as occurring near-universally in this form of disease by conventional PCR-based cohort screens. It left open however the question whether other genome-wide mutations may also commonly occur at high frequency in presentation HCLc disease. To address this, we have carried out WES of 5 such typical HCLc cases, using highly purified splenic tumour cells paired with autologous T cells for germline...
2016: PloS One
https://www.readbyqxmd.com/read/26614904/hairy-cell-leukaemia-variant-disease-features-and-treatment
#13
REVIEW
Estella Matutes, Alejandra Martínez-Trillos, Elias Campo
Hairy cell leukaemia-variant (HCL-V) is a rare B-cell malignancy that affects elderly males and manifests with splenomegaly, lymphocytosis and cytopenias without monocytopenia. The neoplastic cells have morphological features of prolymphocytes and hairy cells. The immunophenotype is that of a clonal B-cell CD11c and CD103 positive but, unlike classical HCL, CD25, CD123 and CD200 negative. The spleen histology is similar to classical HCL and the pattern of bone marrow infiltration is interstitial and/or intrasinusoidal...
December 2015: Best Practice & Research. Clinical Haematology
https://www.readbyqxmd.com/read/26614900/long-term-follow-up-after-purine-analogue-therapy-in-hairy-cell-leukaemia
#14
REVIEW
Monica Else, Claire E Dearden, Daniel Catovsky
Since 2006 when we last reviewed the literature concerning the use of purine analogues in hairy cell leukaemia (HCL), results from several new and updated series have been published. Here we examine these reports and consider their implications for patient management. The two purine analogues pentostatin and cladribine remain the first-line treatments of choice for all patients with HCL. Although they have not been compared in randomised trials, they appear to be equally effective. A complete response is important for the long-term outcome and we look at how best this can be achieved...
December 2015: Best Practice & Research. Clinical Haematology
https://www.readbyqxmd.com/read/26614898/bone-marrow-and-splenic-histology-in-hairy-cell-leukaemia
#15
REVIEW
Andrew Wotherspoon, Ayoma Attygalle, Larissa Sena Teixeira Mendes
Hairy cell leukaemia is a rare chronic neoplastic B-cell lymphoproliferation that characteristically involves blood, bone marrow and spleen with liver, lymph node and skin less commonly involved. Histologically, the cells have a characteristic appearance with pale/clear cytoplasm and round or reniform nuclei. In the spleen, the infiltrate involves the red pulp and is frequently associated with areas of haemorrhage (blood lakes). The cells stain for B-cell related antigens as well as with antibodies against tartrate-resistant acid phosphatase, DBA44 (CD72), CD11c, CD25, CD103, CD123, cyclin D1 and annexin A1...
December 2015: Best Practice & Research. Clinical Haematology
https://www.readbyqxmd.com/read/26614895/epidemiology-and-environmental-risk-in-hairy-cell-leukemia
#16
REVIEW
Tamar Tadmor, Aaron Polliack
Hairy cell leukaemia (HCL) is an orphan subtype of leukaemia which constitutes less than 2% of all leukaemia's, with an incidence of less than 1 per 100,000 persons per annum. Median age at presentation is 55 years and it is 3-4 times more frequent in males. It is also more frequently encountered in whites and less in Asians, Africans and Arabs. The epidemiologic data are multi-factorial and influenced by ethnicity and geographical factors. Other reported associations relate to some environmental exposures and possible occupational factors...
December 2015: Best Practice & Research. Clinical Haematology
https://www.readbyqxmd.com/read/26609034/haematological-profile-of-21-patients-with-hairy-cell-leukaemia-in-a-tertiary-care-centre-of-north-india
#17
Arvind Kumar Gupta, Man Updesh Singh Sachdeva, Jasmina Ahluwalia, Reena Das, Shano Naseem, Prashant Sharma, Narender Kumar, Pankaj Malhotra, Neelam Varma, Subhash Varma
BACKGROUND & OBJECTIVES: Hairy cell leukaemia (HCL) is a B cell neoplasm which constitutes around 2 per cent of all the lymphoid leukaemias. It has a characteristic morphology and immunophenotypic profile. It is important to distinguish HCL from other B cell lymphoproliferative disorders due to availability of different chemotherapeutic agents. This study presents clinical, haematological and immunophenotypic profile of patients with HCL seen over a period of four years in a tertiary care hospital in north India...
October 2015: Indian Journal of Medical Research
https://www.readbyqxmd.com/read/26403440/an-unusual-indication-for-splenectomy-in-hairy-cell-leukaemia-a-report-of-three-cases-with-persistent-splenomegaly-after-chemoimmunotherapy
#18
Nadav Sarid, Humayun N Ahmad, Andrew Wotherspoon, Claire E Dearden, Monica Else, Daniel Catovsky
We describe three cases of relapsed hairy cell leukaemia (HCL) treated with pentostatin plus rituximab. All three achieved bone marrow complete remission but had persistent splenomegaly and hypersplenism. Because of the clinical uncertainty of its significance, they were all splenectomized. The spleen histology showed no evidence of HCL, but a five-fold thickening of the splenic capsule and areas of fibrosis in the red pulp. This process may have contributed to the lack of elasticity and caused the persistent splenomegaly...
December 2015: British Journal of Haematology
https://www.readbyqxmd.com/read/26387749/vemurafenib-for-relapsed-or-refractory-hairy-cell-leukaemia
#19
Holly Baker
No abstract text is available yet for this article.
October 2015: Lancet Oncology
https://www.readbyqxmd.com/read/26269205/hairy-cell-leukaemia-esmo-clinical-practice-guidelines-for-diagnosis-treatment-and-follow-up
#20
T Robak, E Matutes, D Catovsky, P L Zinzani, C Buske
No abstract text is available yet for this article.
September 2015: Annals of Oncology: Official Journal of the European Society for Medical Oncology
keyword
keyword
33280
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"